Novel Vaccination Strategies

Prof. Dr. Stefan H.E. Kaufmann, Scientific member of the Max Planck Society, Founding Director of the Max Planck Institute for Infection Biology, Berlin. More than 500 publications and reviews on immunology and infection. Member of numerous scientific societies and committees and winner of prestigious awards. One of the 100 most cited immunologists in the period of 1981 to 1999.

Colour Plates.PART I.1. Challenges for the Vaccine Developer, including Correlates of Protection (G. Nossal). PART II: VACCINATION AND IMMUNE RESPONSE.2. Shaping Adaptive Immunity against Pathogens: The Contribution of Innate Immune Responses (S. Ehlers & S. Bulfone-Paus).3. Adjuvant-induced Th2- and Th1 -dominated Immune Responses in Vaccination (J. Brewer & K. Pollock).4. Memory (A. Ploss & E. Pamer).5. T-Cell based Vaccines (K. Huster, et al.). PART III: ADJUVANTS.6. Microbial Adjuvants (K. Heeg, et al.). 7. Host-derived Adjuvants (N. Hilf, et al.). 8. Microparticles as Vaccine Adjuvants and Delivery Systems (D. O'Hagan & M. Singh).9. Liposomes and ISCOMs (G. Kersten, et al.). 10. Virosomal Technology and Mucosal Adjuvants (J. Viret, et al.). PART IV: CLASSICAL AND NOVEL VACCINATION STRATEGIES: A COMPARISON.11. Classical Bacterial Vaccines (T. Ebensen, et al.). 12. Subunit Vaccines and Toxoids (M. Lattanzi, et al.). 13. Engineering Virus Vectors for Subunit Vaccines (J. Nkolola & T. Hanke).14. Update on Antiviral DNA Vaccine Research (2000-2003) (D. Franke, et al.).15. Live Recombinant Bacterial Vaccines (S. Clare & G. Dougan).16. Mucosal Vaccination (W. Olszewska & P. Openshaw).17. Passive Vaccination and Antidotes: A Novel Strategy for Generation of Wide-spectrum Protective Antibodies (A. Cassone & L. Polonelli).18. Plant-based Oral Vaccines (K. Wang, et al.). 19. Virus-like Particles: Combining Innate and Adaptive Immunity for Effective Vaccination (M. Bachmann & G. Jennings). PART V: VACCINES FOR SPECIFIC TARGETS.20. Helicobacter Pylori (P. Ruggiero, et al.). 21. Novel Vaccination Strategies against Tuberculosis (S. Kaufmann).22. Rationale for Malaria Vaccine Development (A. Saul, et al.).23. Vaccine for Specific Targets: HIV (R. Kay, et al.). 24. Vaccines against Bioterror Agents (K. Elkins, et al.). PART VI: VACCINES IN THE REAL WORLD: SAFETY, COST EFFICIENCY AND IMPACT OF VACCINATION.25. Imperfect Vaccines and the Evolution of Pathogen Virulence (P. Ewald).26. Cost-Effectiveness of Vaccinations (T. Szucs).27. Immunological Safety of Vaccines: Facts, Hypothesis and Allegations (M. Goldman & P. Lambert). Index.